Stifel analyst Thomas Shrader laid out three scenarios for Medivation Inc MDVN takeover after the biopharma company rejected Sanofi SA (ADR) SNY's $52.50 acquisition bid.
Shrader raised his target price on the stock by $14 to $66, which is also his minimum takeover price for Medivation.
"Overall, we think the ability of a company to enter the growing arena of metastatic castrate-resistant prostate cancer (mCRPC) with a drug as good as xtandi is relatively unique and we expect any deal to get done at a minimum of about $66 per share with an additional conditional payout for Talazoparib," Shrader wrote in a note.
Shrader, who has a Buy rating on the stock, laid out the following three scenarios that could fetch as much as $85 for Medivation.
Scenario 1:Last week, Goldman Sachs said it expects potential takeout value of Medivation near $70 a share.
AT time of writing, shares of Medivation were down 0.62 percent to $57.44.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.